Developer docs
API playgroundTry for free, no card

Search company profiles

Vivimed Labs

Full company profile

uuid00063oj

Namestring
Vivimed Labs
Legal namestring
Vivimed Labs Ltd.
Websiteurl
vivimedlabs.com
Company typeenum
Public
Founded yearint
1991
Descriptiontext

Vivimed Labs Ltd. is a Hyderabad-based, publicly listed (BSE/NSE: 532660) pharmaceutical manufacturer founded in 1991. It operates four WHO GMP and CGMP certified manufacturing facilities across Jeedimetla (Hyderabad), Kashipur (Uttarakhand), and Haridwar, with additional certifications including PIC/S GMP, ISO 13485, CE for medical devices, ISO 9001/14001, and OHSAS 18001. The company runs three core business lines: contract manufacturing (CMO) of capsules, tablets, syrups, nasal sprays, and ointments for global pharmaceutical organizations; supply of niche molecule APIs (including via the UQUIFA business unit); and proprietary branded formulations in ophthalmic, nutraceutical, dermatology, and pain therapeutic segments with products such as Renicol, Lysicon-V, Care Tears, and Dexacort. Named contract manufacturing customers include Novartis (Otrivin), Merck (Nasivion), Cipla, Lupin, Dr. Reddy's, GSK, Pfizer, Gilead Sciences, AstraZeneca, and Teva, and the company serves semi-regulated markets (India, Southeast Asia, Africa, Middle East) while expanding into regulated markets in Europe, the US, Canada, and Australia. The business model is sales-led and B2B, combining professional-services-style contract manufacturing revenue with branded product sales, monetized through direct enterprise engagements without publicly disclosed pricing.

The company has a headcount of 550+ professionals across R&D and manufacturing units, with a contract research lab supporting its own MA and ANDA filings, and reportedly reached 30 market authorizations and ANDAs while expanding its MR field force from 40 to 100. Revenue is generated across multiple dosage platforms including solid orals, sterile products, nasal sprays, eye/ear drops, ointments, and medical devices. Financial trajectory has deteriorated sharply: Q3 FY2026 standalone sales fell 56.2% YoY to Rs 15.99 crore with a consolidated net loss of Rs 16.55 crore, and the company was admitted to India's Corporate Insolvency Resolution Process in April 2026. A Vivimed subsidiary, Vivimed Life Sciences, was part of a ~$15.26M US class action settlement over nitrosamine-contaminated valsartan/irbesartan/losartan, and the company has experienced multiple senior leadership exits including the CEO and CFO in October 2021 and the CFO in February 2024.

Short descriptiontext

Vivimed Labs is a publicly listed Hyderabad-based pharmaceutical company operating four WHO/CGMP certified manufacturing facilities, providing contract manufacturing of formulations for global pharma majors (Novartis, Merck, Cipla, Pfizer, GSK, AstraZeneca, Teva, etc.) alongside APIs (via UQUIFA) and branded ophthalmic, nutraceutical and dermatology products for regulated and semi-regulated markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, finished dosage formulations, active pharmaceutical ingredients, contract manufacturing services, branded formulations
Industry3 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIADAN
Vitamins, Minerals & Supplements (VMS)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing32541
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Manufacturing (CMO)
TypeProfessional Services
Description

Manufacturing pharmaceutical products for various reputed companies including capsules, tablets, syrups, nasal sprays, and ointments for India, Canada, and ROW markets

vivimedlabs.com
2Branded Formulations
TypeOne Time License
Description

Proprietary branded formulations in ophthalmic, nutraceuticals, dermatology, and pain management therapeutic segments

vivimedlabs.com
3Active Pharmaceutical Ingredients (APIs)
TypeTransaction Fee
Description

Manufacturing and supply of niche molecules and APIs to pharmaceutical companies

vivimedlabs.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1UQUIFA
Description

API (Active Pharmaceutical Ingredient) business unit of Vivimed Labs

vivimedlabs.com
+1 more record
Core offering1 text field

Vivimed Labs manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) across multiple delivery platforms including tablets, capsules, syrups, liquids, nasal sprays, ointments, and sterile products. The company operates four WHO and CGMP certified manufacturing facilities that produce contract-manufactured products for global pharmaceutical organizations (such as Novartis's Otrivin and Merck's Nasivion) as well as its own branded formulations in ophthalmic, nutraceutical, dermatology, and pain-management therapeutic segments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Expanded MRs from 40 to 100 within short span
+2 more records
Product overview1 text field

Vivimed Labs operates as a pharmaceutical company with a vertically integrated portfolio spanning active pharmaceutical ingredients (APIs) to finished dosage formulations and new drug delivery systems. The core offering centers on Finished Dosage Formulations, which encompasses four WHO-GMP certified manufacturing facilities producing capsules, tablets, syrups, liquids, sprays, and ointments across therapeutic categories including ophthalmic, nutraceuticals, and dermatology. The company serves both regulated markets (Europe, US, Canada, Australia) and semi-regulated markets (India, Southeast Asia, Africa, Middle East) through three main business models: contract manufacturing (CMO) for global pharmaceutical organizations, proprietary branded formulations, and R&D services supporting regulatory filings. Key manufactured products include Otrivin (for Novartis) and Nasivion (for Merck), while proprietary branded products include ophthalmic offerings like Renicol, Lysicon-V, Care Tears, and Dexacort, alongside nutraceutical and dermatology products.

Product and service8 records
1Finished Dosage Formulations
CategoryPharmaceutical Manufacturing
Description

Comprehensive pharmaceutical formulation manufacturing across solid dosage forms (tablets, capsules), liquid orals, sprays, ointments, and specialized delivery platforms for regulated and semi-regulated markets, produced across four WHO and CGMP certified facilities.

2Contract Manufacturing (CMO)
CategoryContract Manufacturing Services
Description

Contract manufacturing services for pharmaceutical formulations serving India, Canada and ROW markets, including production of capsules, tablets, syrups, nasal sprays, and ointments for various pharmaceutical companies (e.g., Novartis Otrivin, Merck Nasivion).

3Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

Manufacturing and supply of niche molecules and Active Pharmaceutical Ingredients through the UQUIFA business unit, sold to pharmaceutical companies for use in formulations and finished dosage products.

4Branded Formulations - Ophthalmic
CategoryBranded Pharmaceutical Products
Description

Vivimed's proprietary ophthalmic product line including Renicol, Lysicon-V, Care Tears, and Dexacort, marketed as prescription and over-the-counter eye-care products in semi-regulated markets.

5Branded Formulations - Nutraceuticals and Dermatology
CategoryBranded Pharmaceutical Products
Description

Nutraceutical products including enzyme preparations, beta-lactams, antioxidants, and multi-vitamins targeted at women and children, together with dermatological products sold under the Vivimed brand.

6Otrivin (Contract Manufactured)
CategoryContract-Manufactured Pharmaceutical Product
Description

Nasal decongestant spray manufactured at the Haridwar facility for Novartis as part of Vivimed's contract manufacturing operations.

7Nasivion (Contract Manufactured)
CategoryContract-Manufactured Pharmaceutical Product
Description

Nasal drops and sprays including Nasivion and Nasivion Moist manufactured at the Haridwar facility for Merck under contract manufacturing agreements.

8R&D Services
CategoryPharmaceutical R&D Services
Description

Research and development services supporting new drug delivery systems, ANDA filings, and market authorizations, including a contract research lab supporting regulatory submissions.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract manufacturing relationship for Otrivin nasal spray products at the Haridwar facility

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract manufacturing relationship for Nasivion nasal drops and Nasivion Moist spray at the Haridwar facility

3Actavis
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Acquisition of US FDA approved formulation manufacturing facility (2013) as referenced in press releases and acquisition call transcript

vivimedlabs.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

API business investment by OrbiMed Asia as per investor disclosures

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian global pharmaceutical manufacturer with overlapping presence in APIs, finished formulations, and contract manufacturing across ophthalmic, respiratory, and other therapeutic areas; a named CMO customer and direct competitor for global supply contracts.

TypeDirect peer
Description

Indian pharma major with extensive finished dosage manufacturing across multiple delivery platforms and a global CMO/CMIC presence; a named Vivimed customer and a comparable contract manufacturing and branded-generic player.

TypeDirect peer
Description

Integrated Indian pharmaceutical company operating in APIs, branded and generic formulations, and contract manufacturing; named Vivimed customer and a direct comparator in regulated-market generic expansion.

TypeDirect peer
Description

Large Indian pharmaceutical manufacturer with extensive API and finished dosage capabilities across sterile, oral, and injectable dosage forms; co-defendant with Vivimed in the US valsartan contamination litigation and a direct parallel in scale and product mix.

5Hetero Drugs
TypeDirect peer
Description

Indian vertically integrated pharma company with strong API and FDF operations including sterile injectables; co-defendant with Vivimed in the US nitrosamine class action and a direct comparator for contract manufacturing scale and regulatory track record.

TypeDirect peer
Description

Indian pharma focused on finished dosage formulations, soft gels, and sterile injectables with a strong regulated-market presence; comparable as a mid-tier Indian FDF/CMO player expanding into the US, Europe, and Australia.

TypeDirect peer
Description

Indian manufacturer of APIs and finished dosages (tablets, capsules, oral solids) supplying regulated markets; comparable in vertically integrated API-to-FDF model and contract manufacturing customer base.

TypeDirect peer
Description

Indian pharma with API manufacturing and finished formulations across oncology and other specialty therapeutic areas; comparable as a mid-cap Indian pharma with regulated-market ambitions and CMO exposure.

TypeDirect peer
Description

Indian research-driven pharmaceutical company with branded generics, APIs, and contract manufacturing across dermatology and other specialties; comparable for branded niche therapeutic portfolios and regulated-market supply.

TypeBroad incumbent
Description

Large integrated Indian pharmaceutical company spanning APIs, formulations, biologics, and consumer health; broader scale than Vivimed but operates in the same formulation manufacturing and contract development space across regulated and semi-regulated markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vivimed Labs

Pharmaceutical Manufacturingvivimedlabs.com

Vivimed Labs is a publicly listed Hyderabad-based pharmaceutical company operating four WHO/CGMP certified manufacturing facilities, providing contract manufacturing of formulations for global pharma majors (Novartis, Merck, Cipla, Pfizer, GSK, AstraZeneca, Teva, etc.) alongside APIs (via UQUIFA) and branded ophthalmic, nutraceutical and dermatology products for regulated and semi-regulated markets.

What Vivimed Labs does

Vivimed Labs Ltd. is a Hyderabad-based, publicly listed (BSE/NSE: 532660) pharmaceutical manufacturer founded in 1991. It operates four WHO GMP and CGMP certified manufacturing facilities across Jeedimetla (Hyderabad), Kashipur (Uttarakhand), and Haridwar, with additional certifications including PIC/S GMP, ISO 13485, CE for medical devices, ISO 9001/14001, and OHSAS 18001. The company runs three core business lines: contract manufacturing (CMO) of capsules, tablets, syrups, nasal sprays, and ointments for global pharmaceutical organizations; supply of niche molecule APIs (including via the UQUIFA business unit); and proprietary branded formulations in ophthalmic, nutraceutical, dermatology, and pain therapeutic segments with products such as Renicol, Lysicon-V, Care Tears, and Dexacort. Named contract manufacturing customers include Novartis (Otrivin), Merck (Nasivion), Cipla, Lupin, Dr. Reddy's, GSK, Pfizer, Gilead Sciences, AstraZeneca, and Teva, and the company serves semi-regulated markets (India, Southeast Asia, Africa, Middle East) while expanding into regulated markets in Europe, the US, Canada, and Australia. The business model is sales-led and B2B, combining professional-services-style contract manufacturing revenue with branded product sales, monetized through direct enterprise engagements without publicly disclosed pricing.

The company has a headcount of 550+ professionals across R&D and manufacturing units, with a contract research lab supporting its own MA and ANDA filings, and reportedly reached 30 market authorizations and ANDAs while expanding its MR field force from 40 to 100. Revenue is generated across multiple dosage platforms including solid orals, sterile products, nasal sprays, eye/ear drops, ointments, and medical devices. Financial trajectory has deteriorated sharply: Q3 FY2026 standalone sales fell 56.2% YoY to Rs 15.99 crore with a consolidated net loss of Rs 16.55 crore, and the company was admitted to India's Corporate Insolvency Resolution Process in April 2026. A Vivimed subsidiary, Vivimed Life Sciences, was part of a ~$15.26M US class action settlement over nitrosamine-contaminated valsartan/irbesartan/losartan, and the company has experienced multiple senior leadership exits including the CEO and CFO in October 2021 and the CFO in February 2024.

Vivimed Labs firmographics

Firmographics
Name
Vivimed Labs
Legal name
Vivimed Labs Ltd.
Website
https://vivimedlabs.com
Company type
Public
Founded year
1991
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Vivimed Labs is a publicly listed Hyderabad-based pharmaceutical company operating four WHO/CGMP certified manufacturing facilities, providing contract manufacturing of formulations for global pharma majors (Novartis, Merck, Cipla, Pfizer, GSK, AstraZeneca, Teva, etc.) alongside APIs (via UQUIFA) and branded ophthalmic, nutraceutical and dermatology products for regulated and semi-regulated markets.
Ownership category
akta.pro rank

Vivimed Labs industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIADAN
Vitamins, Minerals & Supplements (VMS)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Pharmaceutical manufacturing
  • Finished dosage formulations
  • Active pharmaceutical ingredients
  • Contract manufacturing services
  • Branded formulations

Where Vivimed Labs is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices5 records

Markets served

Vivimed Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Manufacturing (CMO): Manufacturing pharmaceutical products for various reputed companies including capsules, tablets, syrups, nasal sprays, and ointments for India, Canada, and ROW markets
  2. Branded Formulations: Proprietary branded formulations in ophthalmic, nutraceuticals, dermatology, and pain management therapeutic segments
  3. Active Pharmaceutical Ingredients (APIs): Manufacturing and supply of niche molecules and APIs to pharmaceutical companies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Vivimed Labs product offering

Product offering

Core offering

Vivimed Labs manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) across multiple delivery platforms including tablets, capsules, syrups, liquids, nasal sprays, ointments, and sterile products. The company operates four WHO and CGMP certified manufacturing facilities that produce contract-manufactured products for global pharmaceutical organizations (such as Novartis's Otrivin and Merck's Nasivion) as well as its own branded formulations in ophthalmic, nutraceutical, dermatology, and pain-management therapeutic segments.

Product overview

Vivimed Labs operates as a pharmaceutical company with a vertically integrated portfolio spanning active pharmaceutical ingredients (APIs) to finished dosage formulations and new drug delivery systems. The core offering centers on Finished Dosage Formulations, which encompasses four WHO-GMP certified manufacturing facilities producing capsules, tablets, syrups, liquids, sprays, and ointments across therapeutic categories including ophthalmic, nutraceuticals, and dermatology. The company serves both regulated markets (Europe, US, Canada, Australia) and semi-regulated markets (India, Southeast Asia, Africa, Middle East) through three main business models: contract manufacturing (CMO) for global pharmaceutical organizations, proprietary branded formulations, and R&D services supporting regulatory filings. Key manufactured products include Otrivin (for Novartis) and Nasivion (for Merck), while proprietary branded products include ophthalmic offerings like Renicol, Lysicon-V, Care Tears, and Dexacort, alongside nutraceutical and dermatology products.

Differentiator

Problem solved

Functional benefit

Brands

  • UQUIFA: API (Active Pharmaceutical Ingredient) business unit of Vivimed Labs
  • FDF (Finished Dosage Formulations)

Products and services

  • Finished Dosage Formulations Comprehensive pharmaceutical formulation manufacturing across solid dosage forms (tablets, capsules), liquid orals, sprays, ointments, and specialized delivery platforms for regulated and semi-regulated markets, produced across four WHO and CGMP certified facilities.
  • Contract Manufacturing (CMO) Contract manufacturing services for pharmaceutical formulations serving India, Canada and ROW markets, including production of capsules, tablets, syrups, nasal sprays, and ointments for various pharmaceutical companies (e.g., Novartis Otrivin, Merck Nasivion).
  • Active Pharmaceutical Ingredients (APIs) Manufacturing and supply of niche molecules and Active Pharmaceutical Ingredients through the UQUIFA business unit, sold to pharmaceutical companies for use in formulations and finished dosage products.
  • Branded Formulations - Ophthalmic Vivimed's proprietary ophthalmic product line including Renicol, Lysicon-V, Care Tears, and Dexacort, marketed as prescription and over-the-counter eye-care products in semi-regulated markets.
  • Branded Formulations - Nutraceuticals and Dermatology Nutraceutical products including enzyme preparations, beta-lactams, antioxidants, and multi-vitamins targeted at women and children, together with dermatological products sold under the Vivimed brand.
  • Otrivin (Contract Manufactured) Nasal decongestant spray manufactured at the Haridwar facility for Novartis as part of Vivimed's contract manufacturing operations.
  • Nasivion (Contract Manufactured) Nasal drops and sprays including Nasivion and Nasivion Moist manufactured at the Haridwar facility for Merck under contract manufacturing agreements.
  • R&D Services Research and development services supporting new drug delivery systems, ANDA filings, and market authorizations, including a contract research lab supporting regulatory submissions.

Quantifiable outcome

  • Expanded MRs from 40 to 100 within short span
  • +2 more outcomes

Companies that use Vivimed Labs

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Vivimed Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vivimed Labs partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • NovartiscoreStrategic or Co-development PartnerContract manufacturing relationship for Otrivin nasal spray products at the Haridwar facility
  • MerckcoreStrategic or Co-development PartnerContract manufacturing relationship for Nasivion nasal drops and Nasivion Moist spray at the Haridwar facility
  • ActavisminorStrategic or Co-development PartnerAcquisition of US FDA approved formulation manufacturing facility (2013) as referenced in press releases and acquisition call transcript
  • UQUIFAminorStrategic or Co-development PartnerAPI business investment by OrbiMed Asia as per investor disclosures

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Vivimed Labs competitors and assessment

Company assessment

Direct peers

  • Cipla: Indian global pharmaceutical manufacturer with overlapping presence in APIs, finished formulations, and contract manufacturing across ophthalmic, respiratory, and other therapeutic areas; a named CMO customer and direct competitor for global supply contracts.
  • Lupin: Indian pharma major with extensive finished dosage manufacturing across multiple delivery platforms and a global CMO/CMIC presence; a named Vivimed customer and a comparable contract manufacturing and branded-generic player.
  • Dr. Reddy's Laboratories: Integrated Indian pharmaceutical company operating in APIs, branded and generic formulations, and contract manufacturing; named Vivimed customer and a direct comparator in regulated-market generic expansion.
  • Aurobindo Pharma: Large Indian pharmaceutical manufacturer with extensive API and finished dosage capabilities across sterile, oral, and injectable dosage forms; co-defendant with Vivimed in the US valsartan contamination litigation and a direct parallel in scale and product mix.
  • Hetero Drugs: Indian vertically integrated pharma company with strong API and FDF operations including sterile injectables; co-defendant with Vivimed in the US nitrosamine class action and a direct comparator for contract manufacturing scale and regulatory track record.
  • Strides Pharma: Indian pharma focused on finished dosage formulations, soft gels, and sterile injectables with a strong regulated-market presence; comparable as a mid-tier Indian FDF/CMO player expanding into the US, Europe, and Australia.
  • Granules India: Indian manufacturer of APIs and finished dosages (tablets, capsules, oral solids) supplying regulated markets; comparable in vertically integrated API-to-FDF model and contract manufacturing customer base.
  • Natco Pharma: Indian pharma with API manufacturing and finished formulations across oncology and other specialty therapeutic areas; comparable as a mid-cap Indian pharma with regulated-market ambitions and CMO exposure.
  • Glenmark Pharmaceuticals: Indian research-driven pharmaceutical company with branded generics, APIs, and contract manufacturing across dermatology and other specialties; comparable for branded niche therapeutic portfolios and regulated-market supply.

Broad incumbents

  • Zydus Lifesciences (Cadila Healthcare): Large integrated Indian pharmaceutical company spanning APIs, formulations, biologics, and consumer health; broader scale than Vivimed but operates in the same formulation manufacturing and contract development space across regulated and semi-regulated markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Vivimed Labs social profiles

Digital presence

Vivimed Labs compliance and trust

Trust signal

Compliance10 records

Vivimed Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vivimed Labs leadership team

Management profile

Number of profiles

Profiles2 records

Vivimed Labs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vivimed Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vivimed Labs M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivimed Labs

What does Vivimed Labs do?

Vivimed Labs manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs) across multiple delivery platforms including tablets, capsules, syrups, liquids, nasal sprays, ointments, and sterile products. The company operates four WHO and CGMP certified manufacturing facilities that produce contract-manufactured products for global pharmaceutical organizations (such as Novartis's Otrivin and Merck's Nasivion) as well as its own branded formulations in ophthalmic, nutraceutical, dermatology, and pain-management therapeutic segments.

Is Vivimed Labs a public or private company?

Vivimed Labs is a public company. It is classified as public and is currently operating.

When was Vivimed Labs founded?

Vivimed Labs was founded in 1991. It employs 501 to 1,000 people.

Where is Vivimed Labs based?

Vivimed Labs is headquartered in Hyderabad, India, in the Asia region.

How does Vivimed Labs make money?

Three revenue lines are on record. Contract Manufacturing (CMO) is the primary driver. The others are branded Formulations and active Pharmaceutical Ingredients (APIs).

Who are Vivimed Labs's main competitors?

Direct peers on record are Cipla, Lupin, Dr. Reddy's Laboratories, Aurobindo Pharma, Hetero Drugs, Strides Pharma, Granules India, Natco Pharma and Glenmark Pharmaceuticals. Zydus Lifesciences (Cadila Healthcare) is listed as a broad incumbent.

Does Vivimed Labs have an API?

No public API is recorded for Vivimed Labs.

What industry is Vivimed Labs in?

Vivimed Labs's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIADAN, Vitamins, Minerals & Supplements (VMS). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business StandardVivimed Labs reports consolidated net loss of Rs 16.55 crore in the December 2025 quarterVivimed Labs reported a consolidated net loss of Rs 16.55 crore for the quarter ended December 2025, nearly tripling from the net loss of Rs 5.98 crore in the same quarter of the previous year. Sales declined sharply by 56.20% to Rs 15.99 crore from Rs 36.51 crore year-on-year, while operating loss margin turned negative at -68.29%. The financial deterioration marks a significant operational setback for the company compared to the prior year period.Cosmetics BusinessVivimed exhibits at in-cosmetics Global in AmsterdamVivimed will showcase new product launches at in-cosmetics 2018 in Amsterdam, including Jarocol Rich Black and Royal Blue, Jarocol AOL, and its Nisarg natural hair dyes. The company also presents Santé-Clean active concentrates, the first biocidal products using only naturally derived ingredients. Vivimed will be at stand F150.Cosmetics BusinessClariant India lined up to make Vivimed Labs acquisitionClariant India has entered into an agreement to acquire part of Vivimed Labs' personal care portfolio, aiming to expand its product range in sun, skin, hair, oral care, and anti-microbial preservatives. The move strengthens Clariant's presence in Asia and India's growing personal care market.Cosmetics BusinessVivisept GC a naturally derived alternative for preservation of skin, hair and body wash formulations.Vivimed's Vivisept GC, derived from castor bean oil and glyceryl caprylate, provides emolliency and broad-spectrum preservation against microbes. Fenusoft and Fenusoft Q, from fenugreek seeds, offer thickening and conditioning properties for cosmetic formulations.NaturalfieldincTop 10 Cosmetic Raw Material Suppliers in IndiaThis article is a buyers' guide listing and profiling 10 leading Indian suppliers of cosmetic raw materials, highlighting their product portfolios, manufacturing capabilities, and global export reach. The featured suppliers span specialty chemicals, natural ingredients, minerals, and aroma products, serving both domestic and international beauty brands. Key players include Galaxy Surfactants, Vivimed Labs, VedaOils, Gravity Chemicals, Atul Limited, Pharmacos India, Caltron Clays & Chemicals, Bansal Trading Company, Camlin Fine Sciences, and Fineotex Chemical.Business StandardLatest Stock Market News, Sensex Today and Nifty Live UpdatesVivimed Labs Ltd has informed the BSE that its Board of Directors meeting is scheduled for August 13, 2025, to consider un-audited financial results for the quarter ended June 30, 2025, and a proposal for raising funds. The company also announced the closure of its trading window for designated persons from July 1, 2025, until 48 hours after the declaration of these financial results.Cosmetics BusinessVivimed presents new range at in-cosmetics LondonVivimed unveiled its new Jarocol Sapphire Blue semi-permanent dye at in-cosmetics London, stable across pH 4–9. The dye enables formulators to create vibrant fashion shades and natural tones in semi-permanent and temporary hair colour formulations.Cosmetics BusinessVivimed launches hair dyes at in-cosmetics GlobalVivimed launched new hair dyes at in-cosmetics Global, including Jarocol Rich Black and Royal Blue for formulators avoiding Annex III dyes, and Jarocol AOL as a resorcinol-free alternative. The Nisarg natural hair dye range will be commercially available later in 2018, and Santé-Clean active concentrates are the first biocidal products using only naturally derived ingredients.Cosmetics BusinessVivimed Labs Ltd launches Nisarg Moringa Seed OilVivimed Labs launched Nisarg Moringa Seed Oil and Vivabsorb at in-cosmetics Bangkok 2014. The Moringa oil is a naturally extracted moisturiser with Behenic Acid, while Vivabsorb is a UV filter blend for cosmetic formulations. The launch was announced with contact details for sales inquiries.Business StandardVivimed Labs Ltd Share Price Today, 5.85, Vivimed Labs Ltd Stock Price 5.85 on 30th Jun 2026, Vivimed Labs Ltd Stock Price Live NSE/BSEVivimed Labs Ltd reported a consolidated loss of Rs 16.55 crore on total income of Rs 15.99 crore for the quarter ended in 2025, with its promoter holding decreasing to 7.57% by March 2026. The company's stock price was recorded at Rs 5.85 on June 30, 2026, reflecting a 3.94% decline from the previous close. Key financial metrics include a negative price-to-book ratio of -0.56 and trailing twelve-month EPS of Rs -4.21.